Demant A/S (OTCMKTS:WILYY) and Maravai LifeSciences (NASDAQ:MRVI) Head to Head Review

Maravai LifeSciences (NASDAQ:MRVI) and Demant A/S (OTCMKTS:WILYY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Risk & Volatility

Maravai LifeSciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Demant A/S has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Institutional & Insider Ownership

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Maravai LifeSciences and Demant A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Demant A/S	N/A	N/A	N/A

Earnings and Valuation

This table compares Maravai LifeSciences and Demant A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74 million	5.77	-$130.77 million	($0.71)	-5.85
Demant A/S	$3.48 billion	2.20	$233.91 million	N/A	N/A

Demant A/S has higher revenue and earnings than Maravai LifeSciences.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Maravai LifeSciences and Demant A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1	0	3	0	2.50
Demant A/S	0	1	0	2	3.33

Maravai LifeSciences presently has a consensus target price of $5.50, indicating a potential upside of 32.53%. Given Maravai LifeSciences’ higher possible upside, equities research analysts plainly believe Maravai LifeSciences is more favorable than Demant A/S.

Summary

Demant A/S beats Maravai LifeSciences on 8 of the 13 factors compared between the two stocks.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.